PDSB PDS Biotechnology Corporation

PDS Biotechnology Corporation (“PDS Biotechnology”), a clinical-stage immuno-oncology company pioneering the development of novel multifunctional immunotherapeutic products, announced the closing of its merger with Edge Therapeutics, Inc. (“Edge”), following the approval of Edge stockholders on March 14, 2019. Following the merger, Edge will operate as “PDS Biotechnology Corporation”

$3.48
As of 03/05/2021     IEX book   CBOE book


Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Micro cap
Health Care
Biotechnology
USA
USA
09/30/2015
22,261,619
1,529,662
$77,470,434
0.00%
SEC Edgar Online
10-Q
10-K
70465T107
US70465T1079
BJQN8B2

Valuation   (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
0.00
1.18
0.00
-48.34%
0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy